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Abstract: This study was designed to determine the influence of microvesicles (MVs) derived from
multipotent stromal cells isolated from human adipose tissue (hASCs) on retinal functionality in
dogs with various types of retinal degeneration. The biological properties of hASC-MVs were first
determined using an in vitro model of retinal Muller-like cells (CaMLCs). The in vitro assays included
analysis of hASC-MVs influence on cell viability and metabolism. Brain-derived neurotrophic factor
(BDNF) expression was also determined. Evaluation of the hASC-MVs was performed under normal
and oxidative stress conditions. Preliminary clinical studies were performed on ten dogs with retinal
degeneration. The clinical studies included behavioral tests, fundoscopy and electroretinography
before and after hASC-MVs intra-vitreal injection. The in vitro study showed that CaMLCs treated
with hASC-MVs were characterized by improved viability and mitochondrial potential, both under
normal and oxidative stress conditions. Additionally, hASC-MVs under oxidative stress conditions
reduced the number of senescence-associated markers, correlating with the increased expression of
BDNF. The preliminary clinical study showed that the intra-vitreal administration of hASC-MVs
significantly improved the dogs’ general behavior and tracking ability. Furthermore, fundoscopy
demonstrated that the retinal blood vessels appeared to be less attenuated, and electroretinography
using HMsERG demonstrated an increase in a- and b-wave amplitude after treatment. These results
shed promising light on the application of cell-free therapies in veterinary medicine for retinal
degenerative disorders treatment.
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1. Introduction
The etiology of retinal degeneration in dogs is complex, encompassing both acquired and
genetically determined diseases. Amongst the many causes, acquired retinal degeneration could be
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due to infectious disease, trauma, toxicity elevated intraocular pressure and autoimmune factors.
Degeneration can be slow or sudden in onset. For instance, in sudden acquired retinal degeneration
(SARD) the onset of photoreceptor degeneration is usually very rapid, whereas the progress of an
acquired retinopathy could vary depending on cause. Some lesions are stable and focal whereas in
other situations progression to generalized degeneration can be noted [1]. The genetically determined
retinopathies vary in etiology, rate of progression and age of onset. Progressive retinal atrophy
(PRA) is the collective term used for several clinically and genetically heterogenous canine hereditary
retinal dystrophies [1–3]. Most PRA is usually characterized initially by reduced vision in low levels
of illumination due to rod dysfunction, but later total blindness occurs as the result of subsequent
cone degeneration [3,4]. Despite the diversity in the etiology of PRA, there are similarities in the
ophthalmoscopic appearance of the retina towards the end of the degenerative process. The main
features are tapetal hyperreflectivity, vascular attenuation, atrophy of the optic nerve head and
pigmentary changes [1]. Deterioration of the retina causes a loss of function which can be detected by
electroretinographic investigation (ERG) even before the ophthalmoscopic features become visible [5,6].
PRA is considered to be of significant health concern, occurring in over one hundred dog breeds [1,3].
Oxidative stress may play an important role in the pathogenesis of PRA and it has been reported
that the cone degeneration in human retinitis pigmentosa (RP) is related to accumulation of reactive
oxygen species (ROS) and markedly elevated oxygen levels have been observed in the retina after rod
degeneration [7,8]. Moreover, antioxidants have been shown to decrease cone death in several animal
models of retinal degeneration [8–10] and recently it has been proposed that nutritional antioxidant
supplementation could improve the visual function of dogs with retinal degeneration [11]. Several
substances that inhibit photoreceptor loss in animals have been reported, including nerve growth
factor (NGF) and brain-derived neurotrophic factor (BDNF) [12,13]. BDNF has also been recognized as
a promotor of neural stem progenitor cells proliferation through activation of AKT (protein kinase B)
signaling [12]. Beside this neurostimulatory role, Mey and Thanos demonstrated that brain-derived
neurotrophic factor (BDNF) plays a neuroprotective role in an experimental rat model for retinal
degeneration [14]. In this model intra-vitreal administered BDNF has been shown to improve the
process of retinal regeneration. Moreover promising data was presented by Domenici et al. (2014)
who showed that the intravitreal injection and topical instillation of exogenous BDNF in Dilute Brown
Non-Agouti mice strain (DBA/2J) offer protection for retinal ganglion cells [15]. Nevertheless the
therapeutic use of BDNF may be a distant prospect, due to its low penetrability.
Recently, considerable attention has been paid to the role of mesenchymal stromal cells (MSCs)
as a possible treatment for retinal disorders. Progenitor cells are found not only in bone marrow
and adipose tissue, but also in cartilage, muscle, lipid, myocardial cells, glial cells and neurons [16].
Currently, adipose-derived stromal cells (ASCs) are considered to be the most suitable source of MSCs,
mainly due to their highly proliferative activity and immunomodulatory properties, but also due to the
safe method of their isolation [17]. Recently, it has been reported that ASCs exhibit a neuroprotective
effect by secreting trophic/neuroregulatory factors [17,18]. The pro-regenerative potential of ASCs is
explained by their ability to produce and secrete nano- and micro-sized extracellular vehicles (EVs),
which include both exosome and microvesicles (MVs) populations [19,20]. Microvesicles are classified
as heterogeneous population of particles released from membrane plasma, measuring between 30nm to
1µm in diameter. They have also been shown to play an important role in intercellular signaling and they
possess an ability to transfer coding and non-coding RNAs (ncRNAs), including both microRNAs and
long non-coding RNAs (miRNAs, lncRNAs) [21–23]. There is a growing interest in the development of
cell-free therapies based on the use of MVs derived from progenitor cells. Mounting evidence indicates
that the use of MVs represents a novel possible therapeutic tool for tissue regeneration, especially
in degenerative disorders. The MVs stimulate angiogenesis, stem cell differentiation, cell migration
and the activation of anti-apoptotic mechanisms. These cellular processes are crucial in terms of the
amelioration of the clinical signs seen in many retinal degenerations, including PRA and the acquired
retinopathies [19–21,23]. Recently, it has been demonstrated that embryonic stem cell derived MVs are
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able to induce de-differentiation and pluripotency in Müller cells, activities which may result in the
early retinogenic differentiation of those cells [24]. Müller cells are analogous to radial glia in the retina
and are recognized as progenitor retinal cells. They possess the ability to differentiate within multiple
retinal lineages, producing photoreceptors and inner retinal neurons, thus making them potentially
useful for retinal regeneration research [25–28]. Bearing in mind the positive effect of MVs on Müller
cell differentiation, we were interested in determining whether MVs influence the proliferative activity,
apoptosis, senescence and mitochondrial potential of those cells and to test if this pro-regenerative
effect of MVs may be related to BDNF production and the activation of mTOR (mammalian target of
rapamycin kinase), Akt and PI3K (phosphoinositide 3-kinases) pathways. The biological properties
of human adipose-derived multipotent stromal cell-MVs (hASC-MVs) were evaluated using canine
Müller-like cells (CaMLCs) and the effect of clinically administrated hASC-MVs in dogs with retinal
degeneration of different etiologies was assessed.
2. Materials and Methods
2.1. The Preparation of Conditioned Medium from Human Adipose-Derived Multipotent Stromal Cells
(CM-ASC) Rich in Microvesicles (MVs)
The cultures of hASCs used for the procedure have been previously characterized and
described [29]. For this study, cells with an immunophenotype confirming their mesenchymal
origin were used. Their multipotent properties were recognized, and their potential for differentiation
into adipocytes, chondrocytes and osteocytes has been established [29,30]. The cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F12 medium, supplemented with 10% fetal
bovine serum (FBS) and with a 1% antibiotic-antimycotic solution, referred to as a complete growth
medium for hASCs (CGM-hASCs). The cultures of hASCs were maintained in a CO2 incubator (37 ◦C
and 5% CO2) and passaged three times with the trypsin solution TrypLE™ Express (Thermo Fisher
Scientific, Warszawa, Poland). The CGM-hASCs was changed every two days. For the preparation
of the conditioned medium (CM-hASCs), the cells at passage three (p3) were labeled with a PKH67
Fluorescent Cell Linker Kit (Sigma Aldrich, Poznan, Poland) and cultured to obtain 100% confluency.
At high confluency the CGM-hASCs were removed and the cultures were washed three times using
Hanks’ Balanced Salt Solution (HBSS) without the calcium and magnesium. The cultures were then
serum starved for 48 h in a starvation medium (SM) composed of CGM-hASCs without the serum
supplementation. After 48 h, SM was collected and centrifuged initially for 10 min at 300× g. The
supernatants were then collected, centrifuged again for 100 min at 2000× g to remove cell debris and
centrifuged in an Amicon Ultra 15 filter (3000 MWCO, Merck, Poznan, Poland) at 5000× g for 40
min at 4 ◦C to obtain the conditioned medium rich in microvesicles (hASC-MVs). The supernatant
was centrifuged at 20,000× g for 30 min at 4 ◦C in order to obtain the MVs, then removed and the
remaining pellet re-suspended in HBSS. The MVs from the hASCs were stored at −80 ◦C. Total protein
concentration in hASC-MVs was measured using the Bicinchoninic Acid (BCA) Kit Assay Kit (Sigma
Aldrich, Poznan, Poland).
2.2. Isolation and Characterization of Canine Müller-Like Cells (CaMLC)
Retina derived from a 24 h old female German Shepherd Dog fetus was used for the isolation
of primary canine Müller-like cells (CaMLC). Isolated retinal tissue was washed twice using
phosphate-buffered saline (PBS), macerated with a sterile scalpel and homogenized using a sterile pestle.
The homogenates were filtrated using Falcon® 70 µm cell strainers (Corning, Biokom, Janki, Poland),
washed with HBSS and then centrifuged at 300× g for 4 min at room temperature. The pellets were then
suspended in a culture medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s
F12 medium, supplemented with 10% FBS and a 2% antibiotic-antimycotic solution (CGM-pCaMLC).
The CaMLC were cultured at 37 ◦C in humidified 5% CO2, the medium being replaced every two
days. Primary cultures were passaged using a trypsin solution (TrypLE™ Express, Thermo Fisher
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Scientific, Warszawa, Poland) after two days. Secondary cultures were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM), supplemented with 10% FBS and 1% antibiotic-antimycotic
solution (CGM-pCaMLC). The secondary cultures were passaged at around 80% confluency, usually
every 3 days. Before this occurred, the experiment cultures of CaMLC were passaged three times (p3).
The morphology of cultures was monitored using inverted phase-contrast microscope (Axio Observer
A.1, Zeiss, Oberkochen, Germany). The characteristic phenotype of Müller-like cells was determined
using reverse transcription–quantitative polymerase chain reaction (RT-qPCR), the details of which are
described in Section 2.4.
2.3. The Evaluation of the Biological Activity of the Microvesicles Derived from hASCs in Cultures with
CaMLCs under Oxidative Stress Conditions
For the experiment CaMLCs (p3) were inoculated into a 24-well plate at a concentration equal
to 40,000 cells per well. In order to determine their biological activity, the cells were treated with
200 µM of H2O2 in CGM-sCaMLC for 1 h in a 5% CO2 incubator at 37 ◦C. After incubation the cells
were washed with HBSS and then incubated for a further 24 h with hASC-MVs in a concentration
corresponding to the 25 µg/mL of total protein. A comprehensive assessment of cell health state
was then completed, the analysis including evaluation of the apoptosis profile in tested cultures
and the mitochondrial membrane potential of the CaMLC. Measurements were performed using the
Muse™ Cell Analyzer after cell staining with the Muse® Annexin V and Dead Cell Assay Kit and the
Muse® Mitopotential Assay Kit (Merck, Warszawa, Poland). The measurements were repeated at
least three times. Further, mitochondria were visualized using MitoRed staining completed according
to established protocol [31,32]. Also, cultures were counterstained using diamidino-2-phenylindole
(DAPI; 1:1000). The analysis of metabolic activity was performed using an Alamar blue assay as
described previously [33]. The activity of senescence-associated β-galactosidase (β-gal) in cultures
with hASC-MVs, both in normal and oxidative stress conditions, was also determined. For this
purpose, cultures were stained with Senescence Cells Histochemical Staining Kit (Sigma Aldrich,
Poznan, Poland), the blue stained positive cells examined using an inverted microscope (Axio Observer
A.1, Zeiss, Oberkochen, Germany) and analyzed with an ImageJ Pixel Counter [31].
The western blot technique was used for the detection of BDNF in cell homogenates obtained
after the experiment. For the measurement, CaMLCs cultures were washed with Hanks’ Balanced
Salt solution (HBSS) and lysed with ice-cold RIPA extraction buffer supplemented with protease and
phosphatase inhibitors. The protein concentration was determined using the BCA Assay Kit (Merck,
Poznan, Poland). The western blot was completed using the Mini Trans-Blot® system (Bio-Rad Poland
Sp. z.o.o., Warszawa, Poland). Electrophoresis was performed from samples with equal amounts
of protein (30 µg). SDS-PAGE and the protein transfer were completed using protocols described
previously [34,35]. Primary antibodies against BDNF (SAB2108004, Sigma Aldrich, Poznan, Poland)
were prepared at a dilution of 1:250 in Tris/NaCl/Tween buffer (TBST). The secondary antibody used in
the reaction was conjugated with alkaline phosphatase (A9919, Sigma Aldrich, Poznan, Poland). This
antibody was prepared at 1:1000 in TBST. The membranes were developed using BCIP®/NBT-Purple
Liquid Substrate for 10 min. The reaction was stopped by washing the membrane with distilled water.
The signals were captured using the Bio-Rad ChemiDoc™ XRS system and analyzed using Image
Lab™ Software (version 5.2., Bio-Rad Poland Sp. z.o.o., Warszawa, Poland).
2.4. The Reverse Transcription–Quantitative Polymerase Chain Reaction (RT-qPCR)
The mRNA level of the transcripts was evaluated using RT-qPCR. The cells were homogenized
using 0.5 mL of TRI Reagent® (Sigma Aldrich, Poznan, Polska) and totalRNA was isolated using the
Chomczynski and Sacchi method [36]. After totalRNA isolation, genomic DNA residues were removed
using the PrecisionTMDNase kit (Primerdesign Ltd., Cambridge, United Kingdom). The cDNA
synthesis was completed using 0.5 µg of RNA with the Tetro cDNA Synthesis Kit (Bioline Reagents Ltd.,
London, United Kingdom). Oligo (dT) primers18 were used during the reaction. The quantitative PCR
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was performed in a total volume of 10 µL using SensiFast SYBR & Fluorescein Kit (Bioline Reagents
Ltd., London, United Kingdom). The cDNA concentration in the reaction mixture was 1 µL and
the specific oligonucleotide concentration was equal to 400 nM. The sequences of primers used in
the qPCR are listed in Table S1. The qPCR was performed using the CFX Connect Real-Time PCR
Detection System (Bio-Rad Polska Sp. z.o.o., Warszawa, Poland). The gene expression fold change
was calculated based on the quantification cycle (Cq) related to the expression of the housekeeping
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Additionally, CaMLCs marker reaction
products were analyzed by electrophoresis in 2% agarose gel (Novazym, Poznan, Poland) stained with
SYBR™ Safe DNA Gel Stain (Thermo Fisher Scientific, Warszawa, Poland).
2.5. The Clinical Cases
2.5.1. Animals
Ten dogs with behavioral changes that were possibly due to sight deterioration were referred
for ophthalmic examination between the years 2016–2018. The dogs were aged between 2 to 13 years
(8.5 ± 4 years): four animals were pure-bred, six were of mixed breed, six were female and four were
male. In seven of the ten dogs, the clinical histories, results of fundoscopy and absence of other possible
causes of retinal degeneration rendered a tentative diagnosis of progressive retinal atrophy (PRA)
possible. Details of the patients are presented in Table 1. The owner of treated dogs presented written
agreement for publishing these data.
Table 1. Characteristics of animals used in the experiment.
Animal Sex Age(Years) Breed/Type Retinopathy
1 female 12 Crossbred Suspected progressive retinal atrophy (PRA)
2 male 5 Crossbred Suspected progressive retinal atrophy (PRA)
3 female 7 Yorkshire Terrier Cross Suspected progressive retinal atrophy (PRA)
4 male 15 Crossbred Associated with Borrelia sp. infection
5 female 2 Border Collie Associated with systemic infection of unknown etiology
6 female 10 Crossbred Suspected progressive retinal atrophy (PRA)
7 female 7 Welsh Terrier Suspected progressive retinal atrophy (PRA)
8 male 7 German Shepherd Dog Suspected progressive retinal atrophy (PRA)
9 male 12 Continental Spaniel Suspected progressive retinal atrophy (PRA)
10 female 3 Australian Kelpie Unknown
2.5.2. Behavioral Observation
Deterioration in sight was the first sign noticed by all the owners, but initially many suspected that
the hesitation they saw was due to behavioral reasons. Two dogs were working dogs and their problems
were noted as anxiety and nervousness in new places. The dogs started to sniff more intensively,
especially after entering a new room or after getting out of a car. The handlers also noticed that the
dogs were distracted, had difficulty in assessing distance and were hesitant, especially in dark places
and in new surroundings. Other owners had not noticed these behavioral changes, but all commented
that vision was affected initially in low levels of illumination and at night. Dazzle and menace reflexes
were normal, but problems were noted during maze testing. All dogs were put through the maze in a
variety of lighting conditions and noticeable hesitation was observed, especially in dark and dimmed
light. Two dogs had post inflammatory retinal degeneration; in the case of the Collie, this was due to a
chorioretinitis of unknown etiology, but in the crossbred dog, the chorioretinitis was considered to be
associated with a Borelia sp. infection, diagnosed twelve months previously. The infection had been
confirmed using PCR and, according to the owner, the dog’s vision had remained deficient since then.
In both dogs, the owners had noticed the sight problem regardless of the lighting conditions.
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2.5.3. Ophthalmic Examination
The ophthalmic examination included the Schirmer tear test, fluorescein staining, slit lamp
biomicroscopy, tonometry (Tonopen XL, Reichert Technologies, Depew, NY, USA), ultrasound and
fundus examination using both direct and indirect ophthalmoscopy. Fundus changes due to retinal
degeneration were present in all dogs. These changes included bilateral blood vessel attenuation,
tapetal hyperreflectivity and early optic disc atrophy. In the seven dogs in which PRA was suspected
there were no other ocular abnormalities and no history of systemic disease which could cause retinal
degeneration. However in the absence of commercially available DNA based tests, genetic testing for
PRA was not possible for the breeds involved in this study.
2.5.4. Electroretinography
To assess the rod and cone function before MVs administration (Exam I) electroretinography
(ERG) was completed in 9 dogs based on a Short Protocol using a Handheld Multispecies ERG
HMsERG- portable mini-Ganzfeld ERG unit (RetVet Corp, Columbia, MO, USA). The procedure was
performed accordingly to the guidelines for clinical electroretinography in the dog [37]. The dogs
were premedicated intramuscularly with a mixture of dexmedetomidine (Dexdomitor, Orion Pharma,
Warsaw, Poland) 0.005 mg/kg, butorphanol 0.15 mg/kg (Butomidor, Orion Pharma, Warsaw, Poland)
and midazolam 0.1 mg/kg (Midanium 5 mg/mL, Polfa Warszawa SA, Warsaw, Poland). General
anesthesia was induced with intravenous propofol 2 mg/kg propofol 1%, 10 mg/mL (Fresenius Kabi, Bad
Homburg vor der Höhe, Germany) and where prolonged general anesthesia was required, intravenous
propofol was administered as required at 1 mg/kg. Prior to ERG recording, pupils were maximally
dilated with tropicamide (Tropikamidum WZF 1% Polfa Warszawa SA, Warsaw, Poland). Before
ERGs were recorded, the baseline and impedance values were verified. The protocol starts at time 0
with Standard Rod & Cone flash intensity (0.00 Hz, 3 cd/m2/s). After 60 s of dark adaptation another
Standard Rod & Cone flash exam was performed (average of 4 traces, 0.10 Hz, 3 cd/m2/s). This was
then followed after a 5 min adaptation to darkness by a recording of mixed rod-cone response to a
standard flash (average of 4 traces, 0.10 Hz, 3 cd/m2/s). The High Intensity Rod-Cone test was assessed
after a 2-minute dark adaptation (4 traces, 0.05 Hz, 10 cd/m2/s) and the cone flicker test (128 flashes,
30.30 Hz, 3 cd/m2/s). To maintain a consistent level of adaptation in bilateral recordings, room lights
were turned on for 10 min after the recording of the first eye, and then turned off to begin the protocol
of the second eye. A- and b-wave amplitudes were measured from baseline to the first trough and from
that trough to next positive peak. Implicit times were measured from stimulus to the positive peaks a-
and b-waves. For flicker tests, the frequency domain amplitude of the 1st harmonic was extracted. In
the Kelpie after 20 min of dark adaptation Dog Diagnostic Protocol of HMsERG was performed.
2.5.5. The Administration of hASC-MVs
0.1 ml of MVs suspended in HBSS and containing 25 µg/mL of total proteins was injected
intravitreally into one eye of each dog included in the study. The bulbar conjunctiva of the treated eye
was flushed with 3% boric acid (Borasol, 3%, 100 g, Prolab S, Nakło nad Notecia˛, Poland) and 0.5%
solution of jodpovidone (Braunol 10%, Braun, Melsungen, Germany). Corneoscleral forceps were used
to stabilize the eye and a 23 G needle was inserted through conjunctiva and sclera intravitreally, 6 mm
behind the limbus at the 1 o’clock position. The MV solution was injected directly into the vitreous
body in a volume of 0.1 mL. One month following treatment, the behavioral changes were re-evaluated
and both ophthalmoloscopic and ERG examinations were repeated.
2.6. Statistical Analysis
The in vitro assays were performed in triplicate. The data obtained was analyzed using GraphPad
Prism 5 software (La Jolla, CA, USA). Differences between groups were determined using parametric
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assays, un-paired Student’s t–test or one-way analysis of variance (ANOVA). Differences with a
probability of p ≤ 0.05 were considered to be significant.
3. Results
3.1. The Characteristic Features of CaMLCs Used in the Experiment
The Müller-like cells obtained from the canine retina were homogenous, with characteristic
glia-like morphology and centrally located nuclei. They had broad lamellipodia and were symmetrical
in shape. They formed a uniform layer and connected with each other by cellular projections (Figure 1).
The CaMLCs used in the experiment expressed glutamine synthetase (Glul), clusterin (Clu), dickkopf
homolog 3 (Dkk3), S100 calcium binding protein A16 (S100A16), apolipoprotein E (ApoE), aquaporin 4
(AQP4) and vimentin (Vim) (Figure 2), all typical markers for Müller cells.
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Figure 2. The electropherograms of PCR products identified based on their length (base pair/bp). The
CaMLCs expressed specific markers, such as glutamine synthetase (GLUL), clusterin (CLU), dickkopf
homolog 3 (DKK3), S100 calcium binding protein A16 (S100A16), apolipoprotein E (APOE), aquaporin
4 (AQP4) and vimentin (VIM), glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
3.2. The Evalu tion of Biological Properties of hASC-MV –In Vitro
Analysis of CaMLCs’ viability demonstrated that MVs significantly improved health status, both
in normal growth conditions and duri g oxidative stress. Oxidative stress significantly reduced
the percentage of viable cells in CaMLCs, simultaneously increasing the number of early an late
apoptotic cells. The additio of hAS -MVs in oxidative stress resulted i increased viability in the
CaMLCs cultures. The addition of Vs to the H2O2 challenged CaMLC cultures significantly decreased
the percentage of early apoptotic and dead cells, however it did not influence late-apoptotic subset
distribution. (Figure 3).
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Assay K t. The representative dot plots sh w the d stribution of cells into four populations (a). The
populations were determined based on the fluorescence f Annexin V and 7-AAD dye.— ive (l wer left
quadrant; A nexin V −/7-AAD −), early apoptotic (lower right quadrant; Annexin V +/7-AAD −), late
apoptotic (upper right quadrant; An exin V +/7-AAD +), and dead cells (upper left quadrant; An exin
V +/7-AAD +). Comparative statistical analysis was performed i order to determine the influence of
experimental condition on cells’ viability (b) and apoptosis profile (c,d). The presence of dead cells
(nuclear debris) was also determined (e). An asterisk highlights the statistically significant difference
(* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001) and differences between healthy cultures and cultures with
induced oxidative stress are marked with red font. The results are expressed as mean ± S.D.
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The significant decreased viability of cells under oxidative stress, was accompanied by their low
metabolic activity manifested inter alia by low mitochondrial membrane potential (Figure 4). However,
we noticed that introduction of hASC-MVs significantly increased the number of CaMLCs with high
mitochondrial potential under oxidative stress. This was also associated with a reduced number of
cells classified as live but with low mitochondrial potential, both noted in cultures treated with H2O2
under control conditions (Figure 4c). A significant increase of non-viable and non-viable depolarized
CaMLCs was, also noted in cultures propagated under oxidative stress conditions and in the presence
of MVs (Figure 4d,e).
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Figure 4. The influence of MVs on mitochondrial membrane potential in CaMLCs cultures both under
normal and oxidative stress conditions induced using H2O2. The analysis was performed using the
Muse® Mitopotential Assay Kit. The representative graphs (a) show gated cells with quadrant marker
providing data on four cell populations—live lls ith depolarized mitochondrial membrane (lower
left quadrant), live cells with intact mitochondrial memb ne (lowe right quadrant), dead/depolarized
cells (upper left quadrant) and dead cells (upper right quadrant). The an lysis w s performed in
triplicate, and the comparative statistic was performed (b–e). An asterisk marks a statistically significant
difference (* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001). Differences between healthy cultures and cultures
with induced oxidative stress are marked with red font. The results are expressed as mean ± S.D.
The results of an Alamar blue assay showed that the addition of hASC-MVs significantly improved
the metabolic activity of CaMLCs under oxidative stress conditions. The hASC-MVs also increased
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the metabolism of cells in healthy cultures, but this change was not statistically significant (Figure 5).
These observations are in a good agreement with the images showing mitochondrial morphology and
analysis of the fluorescence signal intensity derived from mitochondria is also in line with the results
indicating mitochondrial membrane potential.
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Figure 5. The analysis of mitochondrial morphology and activity, based on fluorescence signal intensity
and analysis of CaMLCs met bolic activity. The control cultures were propag ted usi typical
growth medium (a) as well s under oxi ative stress conditions (b). The rphology of cells and
mitochondria activity was determined also in cultures with introduced hASC-MVs (c,d, respectively).
The hASC-MVs were labeled with green PKH67 dye, notice in cultures as green-yellow dots (magnified
square fields). Images were analyzed under 60-fold magnification (scale bar 200 µm). The insensitivity
of fluorescence derived from stained mitochondria was measured using ImageJ software (e). Metabolic
activity was measured using Alamar Blue assay (f). The obtained results were used for statistical
analysis. The significant differences were marked using an asterisk (* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤
0.001). Differences between healthy cultures and cultures with induced oxidative stress are additionally
marked with red font. The results are expressed as mean ± S.D.
The analysis of senescence marker β-galactosidase showed that MVs decrease the percentage
of senescent cells in CaMLCs cultures, with the most significant senolitic effect of MVs being noted
under normal conditions. The analysis of mRNA levels for telomerase reverse transcriptase (TERT)
and mitochondrial superoxide dismutase 2 (SOD-2) showed that MVs did not alter their expression
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in CaMLCs cultures. Nevertheless, both TERT and SOD-2 were upregulated in cultures in which
oxidative stress had been induced (Figure 6).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 12 of 22 
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Figure 6. The analysis of the s nolytic acti f Vs both in control and oxidative stress induced
cultures (a–d). The β-galactosidase positive cells are marke it r arrows. The number of cells was
counted using ImageJ software and analyzed statistically (e). The expression of markers associated
with cell senescence was measured using RT-qPCR. Following transcripts were measured: telomerase
reverse transcriptase (TERT; f); mitochondrial superoxide dismutase 2 (SOD-2; g) and vimentin (VIM; h).
The transcripts levels were normalized (Qn) to the reference gene (here: Glyceraldehyde-3-Phosphate
Dehydrogenase; GAPDH). The normal z d values (Qn) were nalyzed using statistical tests. The
significant differences are marked with asterisks (* p < 0.05; ** p < 0.01 a *** p < 0.001) and differences
between healthy cultures and cultures with induced oxidative stress are marked in red font. The results
are expressed as mean ± S.D.
The BDNF expression determined on mRNA and protein levels (the concentration of intracellularly
accumulated protein) was stable in CaMLCs maintained in the control cultures. Oxidative stress in
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CaMLCs was associated with a significant increase of mRNA for BDNF, but the addition of hASC-MVs
did not influence the transcript level. BDNF concentration decreased after oxidative stress inducement,
but treatment with MVs significantly (p < 0.05) improved its accumulation in CaMLCs. The profile of
the mTOR gene expression was similar to the mRNA expression of BDNF. It appeared that oxidative
stress induced in CaMLCs was also associated with increased levels of mTOR transcripts, but again
the MVs did not alter the expression of mTOR. It was also noted that the mRNA levels for Akt and
PI3K in CaMLCs appeared to have similar patterns of expression. Generally, the addition of MVs to
healthy cultures significantly decreased the transcripts levels, while under oxidative stress it caused an
increase of mRNA levels for Akt and caused a significant increase for PI3K. The expression of Akt and
PI3K was significantly increased in cultures treated with hASC-MVs in comparison with the control
cultures (Figure 7).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 13 of 22 
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Figure 7. The influence of MVs on the expression of brain derived neurotrophic factor (BDNF) and
elements of PI3K/Akt/mTOR signaling pathway. F acc mulation in c lls was determined using
the Western blot technique (a). The densitometry analysis was performed using ImageLab software,
the amount of accumulated protein was determined in relation to the β-actin (b). The mRNA levels for
BDNF (c), mTOR (d) AKT (e) and PI3K (f) were establish using RT-qPCR, and quantitative analysis
was performed in reference to GAPDH. The obtained results i.e., normalized values (Qn) were tested
using statistical methods. A asterisk marks statistically significant differences (* p ≤ 0.05, ** p ≤ 0.01
and *** p ≤ 0.001) and differences between healthy cultures and cultures with induced oxidative stress
are marked in red font. The results are expressed as mean ± S.D.
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3.3. The Evaluation of Biological Properties of hASC-MVs–In Vivo
3.3.1. Behavioral Observations
Eight of ten dogs demonstrated an improvement in behavior in both dark and dim lighting
conditions. In the remaining one dog the owners did not notice any change. The observations before
and after therapy in both dark and dim lighting conditions are described in Table 2.
Table 2. The behavioral features of animals before and after therapy with hASC-MVs.
Features Before Therapy After Therapy p Value
General
behavior
Anxiety, reluctance towards with the
handler, aggression with other dogs,
problems negotiating obstacles, difficulties
in dark rooms, visible stress and frustration.
Calmer, more confident and more tolerant
with other dogs. Still a need to adapt after
entering dark room but the time needed
was shorter. Training was easier on days
without very bright light.
p < 0.05
Tracking Lack of motivation, problems with changesin direction and easily distracted.
Calmer, very precise, focused on the line of
scent, no frustration when the track
changed, low stress.
p < 0.05
Other relevant
comments
Problems with catching objects and judging
distances
Slow improvement in catching objects,
more dynamic but still problems in dim
lighting at night.
p < 0.05
In eight of the test dogs maze testing revealed that following hASC-MVs therapy these dogs
expressed less hesitation in the dark and no hesitation in dim lighting conditions. The dog which
showed no improvement was the five year old crossbred with suspected PRA, the second was the fifteen
year old cross-bred with retinal degeneration due to inflammation associated with Borrelia infection.
3.3.2. Ophthalmic Examination
Funduscopic changes were not seen during the first month following treatment. Representative
image of the analysis is presented in the Figure 8. Three year old Kelpie with a retinopathy of unknown
origin, noticeable fundus changes were found following treatment. Initially there had been focal areas
of hyperreflectivity as well as areas of pigmentation in the tapetal fundus. After three months we
observed less pigment in the peripheral tapetal fundus, although some areas of hypereflectivity had
appeared nearer to the optic disc (Figure 8).
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(c). A noticeable decrease in tapetal pigmentation was observed, but areas of focal hyperreflectivity
were noted nearer to the optic disc.
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3.3.3. Electroretinography (ERG) Post hASC-MV Administration
Short protocol electroretinography was completed under the same conditions as those prior to the
MV treatment. The a- and b-wave amplitudes were measured from the baseline to the first trough and
from that trough to the next positive peak. Implicit times were measured from the stimulus to the
positive peak. For the flicker tests, the frequency domain amplitude of the first harmonic was extracted.
Analysis showed that both the a and b-wave amplitudes significantly increased after MV injection
(Figure 9a). Analysis of standard rod cone w1/flash demonstrated an increase in the a- and b-wave
amplitude after treatment, although the significant improvement was observed only for the a-wave.
(Figure 9b–d). The first and second standard rod-cone 3cd, as well as the high intensity rod- cone
10cd demonstrated that MV therapy did not influence the implicit time, but significantly improved
the a- and b-wave amplitudes (Figure 9e). The flicker analysis revealed that the b-wave implicit time
increased, but the difference was not statistically significant. There was a significant increase in the
b-wave amplitude after hASC-MVs injection.
According to the Dog Diagnostic Protocol (long protocol) performed in one of ten dogs a- and
b-wave implicit time remained stable whereas a- and b-wave amplitude increased in rod and rod cones
responses (Table 3) Additionally improvement in the dynamic process of dark adaptation was seen
(Figure 10).
Figure 9. Cont.
J. Clin. Med. 2019, 8, 510 15 of 21
Figure 9. The results of ERG measurements. Mean values of ERG recordings obtained for nine dogs.
The analysis included comparison of implicit times as well as a- and b-wave amplitudes before and
after hASC-MVs implantation. The analysis was based on determination of following parameters:
Standard Rod-Cone w/1 flash using implicit time (a) and amplitudes (b); First Standard Rod-Cone
3cd with implicit time (c) and amplitudes (d); Second Standard Rod-Cone 3cd with implicit time (e)
and amplitudes (f); Hi Intensity Rod-Cone 10cd with implicit time (g) and amplitudes (h); Flicker b
amplitude implicit time (i) and Flicker b-wave amplitude (j). Statistically significant differences are
indicated with asterisks (*). The statistically significant differences were determined at p ≤ 0.05 (*) and
p ≤ 0.001 (***). The results are expressed as mean ± S.D.
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Table 3. The results of ERG analysis using long protocol. Study performed on the Kelpie dog with
retinal degeneration of unknown etiology.
Parameter Before hASC-MVsTreatment
After hASC-MVs
Treatment
Rod1
a (ms) 5.6 3.9
b (ms) 56.7 51.8
a-wave (µV) 3.3 0.7
b-wave (µV) 12.8 23.5
Rod2
a (ms) 14.4 16.5
b (ms) 55 51.9
a-wave (µV) 0.6 1.3
b-wave (µV) 20.3 49.9
Rod3
a (ms) 20 3
b (ms) 56.7 51.9
a-wave (µV) 0.8 2.2
b-wave (µV) 23.3 49.9
Rod4
a (ms) 13.9 18.4
b (ms) 56.4 51
a-wave (µV) 0.6 0.4
b-wave (µV) 23.4 52.8
Rod5
a (ms) 2.2 20.2
b (ms) 56.2 51.9
a-wave (µV) 1.3 1.4
b-wave (µV) 31.1 56
Standard rod and cone
responses
a (ms) 13.3 12.1
b (ms) 33.2 30.9
a-wave (µV) 33.9 43.1
b-wave (µV) 79.9 105
High intensity rod and
cone response
a (ms) 12.8 11.2
b (ms) 32.8 30.5
a-wave (µV) 41.6 48
b-wave (µV) 87.1 101.9
Cone response
a (ms) 9.1 7.7
b (ms) 26.1 25.5
a-wave (µV) 5.6 4.4
b-wave (µV) 17.2 13
Cone flicker response b (ms) 25.2 25.2
b-wave (µV) 34.2 29.2
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Figure 10. Representati e electr reti r tr ces rese ti g ark adaptation before (a) and after
(b) MV injection. There is a significant difference in the amplitude changes during the dark adaptation.
Each color-marked trace represents a time-delayed recording made during 20 min of ERG examination
consisting of 5 measurements every 4 min.
4. Discussion
This study has de str t f r t first ti t ff t f - s on Ca LCs in both
normal and oxidative stress conditions. We examined the influe ce of hASC-MVs on CaMLCs viability,
proliferative and metabolic activity, as well as the expres ion of BDNF. I addition the role of hASC-MVs
on mitochondrial membra e potential, the xpr ssion of senescence markers as w ll as the oxidative
stress markers have been determined. The possible therapeutic potential of hASC-MVs w s evaluated
in dogs with retinal degeneration and to th best of ur knowledge this is the first r port showing a
potential applicat on of MV’s in the treatment of can e r tinal degeneratio s.
An in vitro odel of t i l gical activity of MVs obtained from
hASCs. These CaMLCs pres nted as glial-like morphotype and were ident fi d using markers typical
for Muller-like c lls [38–40]. The results indicated that MVs significantly improve the viability of these
cells, both under normal growth conditions as well as under oxidative stress. The results ar in accord
with the Eldh et al. study (2010) which demonstrated that exosomes derive from mast cells under
oxidative stress may have the ability to induce tolerance to oxidative stress in recipient cells [41]. Further
it was shown that MVs derived from human Wharton Jelly mesenchymal stromal cells (hWJMSCs)
may have therapeutic potential and could protect kidney cells against renal ischemia/reperfusion injury
(IRI) by mitigating the oxidative stress [42]. In our study we have demonstrated that MVs derived
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from hASCs may alleviate the oxidative stress effect in CaMLCs by improving their mitochondrial
potential. This is also in good agreement with studies of Yu et al. (2015) who showed that exosomes
derived from mesenchymal stromal cells may contribute to increased survival, reduced apoptosis and
may preserve mitochondrial membrane potential in neonatal cardiomyocytes cultured under hypoxic
conditions [43]. Furthermore, our study also indicated on a positive senolytic action of hASC-MVs
toward canine Müller-like cells. The senolytic effect of hASC-MVs was related to decreased expression
of senescence associated markers i.e., β-galactosidase and vimentin in CaMLCs, but also with their
increased metabolic activity Obtained results correspond with the studies showing that human induced
pluripotent stem cell-derived exosomes may have an anti-senescence effect on high glucose-injured
human umbilical vascular endothelial cells (HUVECs) [44]. Our study has also demonstrated that
MVs may contribute to the greater functionality of CaMLCs in oxidative stress conditions, improving
their production of BDNF. It has been previously shown that hASCs can provide neurotrophic growth
factors, particularly BDNF, to injured nerves [45]. Additionally, Martins et al. (2017) showed that the
secretome of mesenchymal stromal cells is able to promote axonal outgrowth in central nervous system
(CNS) neurons and that this effect may be mediated by BDNF [46].The results of in vitro studies clearly
demonstrate that vesicles derived from ASC are able to regulate metabolism, cell senescence and
apoptosis of CaMLCs. These cytophysiological features greatly affect the therapy outcome. Indeed,
MSC-derived vesicles were shown to have positive impact on tissue repair via various pathways,
mainly those associated with cell death and senescence, for instance resulting from ischemic injury [47].
It is also emphasized that therapeutic effect of mesenchymal stem cells relies on their paracrine effect
and immunomodulatory properties [47,48], due to this fact various cell-free therapies based on MVs
implantation are being evaluated [49].
In our study, we were interested whether the hASCsMVs may improve retinal function. The
clinical part of the study was completed in canine patients with different types of retinal degeneration.
In eight of the ten treated animals we have shown that the intravitreal injection of MVs in dogs with
retinal degeneration of both of presumed genetic and acquired etiologies lead to a reversal of adverse
behavioral problems and an improvement in maze performance. Our data corresponds with previous
results showing a positive effect of bone marrow derived mesenchymal stem cells in the treatment of
human retinitis pigmentosa patients. Siqueira et al. (2015) demonstrated that quality of life in these
patients was transiently but significantly improved [50].
The dogs included in our research already had advanced signs of retinal degeneration,
demonstrating blood vessel attenuation and varying degrees of tapetal hyperreflectivity.
The ophthalmoscopic changes observed three months after treatment are not dramatic, but they
seemingly parallel the improvements in both the behavioral and electroretinographic results. Simple
screening electroretinography is routinely used in the investigation of retinal degenerations in animal
models [51] and in short protocol electroretinography only gross retinal function can be determined.
We were able use the technique to demonstrate that intra-vitreal MVs implantation improved retinal
functionality. Increases in the a- and b-wave amplitudes were recorded, indicating improvement in
photoreceptor and Muller cell functions respectively. The Dog Diagnostic Protocol performed in one
dog revealed also the improvement in process of dark adaptation of rod photoreceptors. The ERG
results obtained in particular animals correlated with both their improved behavioral activity and
performance in maze testing. However, further studies are required to substantiate our preliminary
results and to assess the potential value of MVs implantation in the long term outcomes.
5. Conclusions
The results of this study indicate a potential future use of MVs derived from adipose-tissue stromal
cells in the treatment of degenerative canine retinal disorders. MVs contributed to increased viability
and metabolic activity of Müller like-cells in vitro, whilst their intra-vitreal administration significantly
improved photoreceptor and Müller cell function. The results also shed promising light on application
of MVs-based therapy in the treatment of retina degeneration.
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